GENE ONLINE|News &
Opinion
Blog

2020-09-12| Asia-Pacific

Relaxation of CBD Restriction Sparks Controversy

by Judy Ya-Hsuan Lin
Share To

THC Global Group Limited embraces an interim Therapeutic Goods Administration (TGA) decision to down schedule cannabidiol (CBD) medicines to Schedule 3 to allow easier access of low-dose CBD without prescriptions.

By Judy Ya-Hsuan Lin

THC Global’s Southport Facility is one of the world’s largest pharmaceutical GMP cannabis manufacturing facilities. Because they own Crystal Mountain, a fast-growing hydroponics equipment wholesaler, they can supply wholesalers and retailers in Europe and North America’s rapidly expanding cannabis sector. The CBD market analysis company Brightfield Group predicted that the cannabis industry’s value would hit 22 billion by 2022. Although the down-scheduling ensures a well-documented safety profile, higher accessibility and better affordability to patients, the TGA decision sparks controversy over two parties holding different opinions on the expanding use of CBD.

The THC decision to expand CBD legalizes many activities and conveniences in daily life, but limited clinical evidence demonstrates the extent of therapeutic effectiveness and safety for individuals and patients. Thus, the decision poses potential suspicion. Zsolt Csonka, the founder of Adriaen Block restaurant located in Astoria, New York, uses CBD-contained concomitants in his dishes to optimize customers’ tasting experience.

Besides, he shared his experience that it usually takes 4-5 shots of Whiskey for people to feel relaxed but only two shots containing CBD to impose the same effect. Dr. Chris Freeman, the Pharmaceutical Society of Australia national president, told the Australian Journal of Pharmacy an opposing opinion. He is concerned about the lack of clinical evidence of low-dose CBD’s therapeutic efficacy for patients and the current absence of enough information to ensure patients access these medicines appropriately.

Related Article: Weekly in Asia(0414-0420)

References:

https://www.proactiveinvestors.com.au/companies/news/928601/thc-global-welcomes-interim-tga-decision-to-down-schedule-cbd-medicines-to-allow-pharmacy-access-without-prescription-928601.html

 

©www.geneonline.com All rights reserved. Collaborate with us: [email protected]
Related Post
R&D
Scientists Uncover More Evidence of CBD’s Effect on Epileptic Seizures in Children
2023-02-18
The FDA Issued its First Formal Warning to Companies Selling Delta-8 THC Products
2022-05-05
MGC Pharmaceuticals Enters Partnership with Sciensus Rare for Distribution of Cannabinoids to Treat Refractory Epilepsy, Dementia and Alzheimer’s in the EU and UK
2022-04-05
LATEST
World Vaccine Congress Washington 2025 Recap: Urgent Calls for Trust, Tech, and Global Access
2025-04-25
Astellas’ Transformation Journey: From Merger to Global Player, Betting on the Edge of Innovation and Risk?
2025-04-25
Roche Announces Massive 50 Billion Dollar Investment in the United States
2025-04-25
Steminent Stands Ready to Showcase Novel MSC-based Therapy for Spinocerebellar Ataxia at Global Stage
2025-04-24
Arkansas Medicaid Work Requirements Led to Coverage Loss for a Significant Number of Recipients
2025-04-24
Boehringer agrees new partnership to advance first-in-class precision cancer therapies
2025-04-24
Bristol Myers Squibb Schizophrenia Drug Fails Pivotal Test as an Add-On to Antipsychotics
2025-04-24
EVENT
2025-04-25
AACR Annual Meeting 2025
Chicago, U.S.A
2025-05-03
29th Taiwan Joint Cancer Conference 2025
Taipei, Taiwan
2025-05-05
Swiss Biotech Day 2025
Basel, Switzerland
2025-05-13
ASGCT 28th Annual Meeting 2025
New Orleans, U.S.A.
2025-05-30
ASCO Annual Meeting 2025
Chicago, U.S.A
2025-06-11
ISSCR 2025 Annual Meeting
Hong Kong
Scroll to Top